<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152876</url>
  </required_header>
  <id_info>
    <org_study_id>PON MISE n. F/050011/01/X32</org_study_id>
    <nct_id>NCT04152876</nct_id>
  </id_info>
  <brief_title>Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power</brief_title>
  <official_title>Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Genetics and Biophysics CNR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project aims to improve the understanding of a significant group of rare diseases both
      from a genetic/diagnostic and clinical/experimental point of view and aims to develop one or
      more diagnostic protocols.

      The study will be conducted through the application of complementary experimental strategies,
      ranging from the clinical, genetic and molecular characterization of the pathology to the
      search for rare variants and the development of cellular disease models.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Clinical evaluation of patients and relatives

        2. High throughput analysis of genetic variants in genome exomes

        3. Genotype-phenotype association testing

        4. Identification of genetic risk variants for rare diseases
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of genetic variants responsible for rare diseases</measure>
    <time_frame>Two years</time_frame>
    <description>Analysis of exome sequencing data; annotation of genetic variants; selection of variants present in cases and absent in controls</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rare Diseases</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with rare disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>Healthy parents and relatives</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for DNA extraction
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected from the Center for rare diseases of the IRCCS Neuromed, and at
        IGB CNR according to specific inclusion criteria. Approximatey 300 subjects, recruited with
        a family-based approach, will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients affected by: SLA, Incontinentia Pigmenti type II, Rett Syndrome, Paget
             Disease, Pompe Disease, Immunodeficiency, Centromeric instability and Facial
             anomalies, Cortical malformations and malignant epileptic encephalopathies

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diego Centonze, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Neurology Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diego Centonze, MD</last_name>
    <phone>+39 0865915212</phone>
    <email>centonze@uniroma2.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Alba Di Pardo, PhD</last_name>
      <phone>0865915212</phone>
      <email>dipardoa@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Diego Centonze</investigator_full_name>
    <investigator_title>Head of Neurology Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

